医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
17期
71-73
,共3页
乙肝%臭氧%阿德福韦脂胶囊%随访观察
乙肝%臭氧%阿德福韋脂膠囊%隨訪觀察
을간%취양%아덕복위지효낭%수방관찰
Hepatitis b%Ozone%Adefovir Dipivoxil Capsules%Fol ow-up observations
目的：总结臭氧联合阿德福韦脂胶囊治疗乙肝四年随访情况。方法：采取回顾性方法对我院2010年1月-2013年12月来就诊治疗﹑符合观察标准的乙肝患者112例，均采取臭氧联合阿德福韦脂胶囊治疗，并对4年来的治疗随访情况进行总结与分析。结果：患者随访后1-4年的ALT﹑TBil﹑ALB和Child-pugh评分较治疗前有明显的改善，且各组数据比较有统计学意义(P＜0.05)。随访1-4年患者的HA﹑PCⅢ和CⅣ较患者治疗前有明显的改善，且数据的比较差异有统计学意义( P＜0.05)。随访1年后112例生存，生存率100.0%；随访2年后110例生存，生存率98.2%；随访3年后109例生存，生存率97.3%；随访4年后107例生存，生存率95.5%。治疗后4年的随访观察，共有11例出现病情反弹，反弹率为9.8%。5例患者转化为肝硬化，3例患者转化为肝癌。本组患者治疗中未见有任何的不良反应发生。结论：临床中对于乙肝患者采取臭氧联合阿德福韦脂胶囊治疗效果明显，远期效果也较好，改善患者预后，有效的降低病情恶化，提高患者生活质量。
目的：總結臭氧聯閤阿德福韋脂膠囊治療乙肝四年隨訪情況。方法：採取迴顧性方法對我院2010年1月-2013年12月來就診治療﹑符閤觀察標準的乙肝患者112例，均採取臭氧聯閤阿德福韋脂膠囊治療，併對4年來的治療隨訪情況進行總結與分析。結果：患者隨訪後1-4年的ALT﹑TBil﹑ALB和Child-pugh評分較治療前有明顯的改善，且各組數據比較有統計學意義(P＜0.05)。隨訪1-4年患者的HA﹑PCⅢ和CⅣ較患者治療前有明顯的改善，且數據的比較差異有統計學意義( P＜0.05)。隨訪1年後112例生存，生存率100.0%；隨訪2年後110例生存，生存率98.2%；隨訪3年後109例生存，生存率97.3%；隨訪4年後107例生存，生存率95.5%。治療後4年的隨訪觀察，共有11例齣現病情反彈，反彈率為9.8%。5例患者轉化為肝硬化，3例患者轉化為肝癌。本組患者治療中未見有任何的不良反應髮生。結論：臨床中對于乙肝患者採取臭氧聯閤阿德福韋脂膠囊治療效果明顯，遠期效果也較好，改善患者預後，有效的降低病情噁化，提高患者生活質量。
목적：총결취양연합아덕복위지효낭치료을간사년수방정황。방법：채취회고성방법대아원2010년1월-2013년12월래취진치료﹑부합관찰표준적을간환자112례，균채취취양연합아덕복위지효낭치료，병대4년래적치료수방정황진행총결여분석。결과：환자수방후1-4년적ALT﹑TBil﹑ALB화Child-pugh평분교치료전유명현적개선，차각조수거비교유통계학의의(P＜0.05)。수방1-4년환자적HA﹑PCⅢ화CⅣ교환자치료전유명현적개선，차수거적비교차이유통계학의의( P＜0.05)。수방1년후112례생존，생존솔100.0%；수방2년후110례생존，생존솔98.2%；수방3년후109례생존，생존솔97.3%；수방4년후107례생존，생존솔95.5%。치료후4년적수방관찰，공유11례출현병정반탄，반탄솔위9.8%。5례환자전화위간경화，3례환자전화위간암。본조환자치료중미견유임하적불량반응발생。결론：림상중대우을간환자채취취양연합아덕복위지효낭치료효과명현，원기효과야교호，개선환자예후，유효적강저병정악화，제고환자생활질량。
Objective: To summarize the Ozone combine Adefovir Dipivoxil Capsules treatment of hepatitis b 4 years fol ow-up. Methods:Retrospective methods in our hospital in January 2010 - December 2013 to clinic treat -ment, accord with standard of observation of 112 cases of patients with chronic hepatitis b, the Ozone is adopted combine Adefovir Dipivoxil Capsules treatment, and treatment for four years fol ow-up summary and analysis. Result:Before and after the patients were fol owed for 1-4 years, ALT, TBil, ALB and Child-pugh score improved significantly compared with the treatment, and each set of data was statistical y significant (P <0.05). 1-4 years fol ow-up in patients with HA, PC Ⅲ and C Ⅳ patients before treatment had obvious improvement, and data com -parison difference was statistical y significant (P < 0.05). Fol ow-up of 1 year after 112 cases of survival, the survival rate was 100.0%; 110 cases were fol owed up for 2 years survival, survival rate was 98.2%; 109 cases were fol owed up for 3 years survival, survival rate was 97.3%; 107 cases were fol owed up for 4 years to survive, the survival rate was 95.5%. Treatment and after 4 years of fol ow-up, there were 11 cases of il ness bounce, bounce rate was 9.8%. 5 patients into liver cirrhosis, 3 patients were converted to liver cancer. In this group of patients did not see any adverse reactions occur.Conclusion:For clinical hepatitis B patients to take the Ozone combine Adefovir Dipivoxil Capsules treatment effect is obvious, the long-term effect is better also, improve the prognosis of patients, effectively reduce the deterioration, improve patient quality of life.
